Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15:131. https://doi.org/10.1186/s13045-022-01351-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alix-Panabières C, Pantel K (2021) Liquid biopsy: from discovery to clinical application. Cancer Discov 11:858–873. https://doi.org/10.1158/2159-8290.CD-20-1311

Article  PubMed  Google Scholar 

Pascual J, Attard G, Bidard FC et al (2022) ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33:750–768. https://doi.org/10.1016/j.annonc.2022.04.003

Article  CAS  Google Scholar 

Dang DK, Park BH (2022) Circulating tumor DNA: current challenges for clinical utility. J Clin Invest 132:e154941. https://doi.org/10.1172/JCI154941

Article  CAS  PubMed  Google Scholar 

Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859–1864. https://doi.org/10.1038/s41591-020-1063-5

Article  CAS  PubMed  Google Scholar 

Cohen SA, Liu MC, Aleshin A et al (2023) Practical recommendations for using ctDNA in clinical decision making. Nature 619:259–268. https://doi.org/10.1038/s41586-023-06225-y

Article  CAS  PubMed  Google Scholar 

Chakravarty D, Solit DB (2021) Clinical cancer genomic profiling. Nat Rev Genet 22:483–501. https://doi.org/10.1038/s41576-021-00338-8

Article  CAS  PubMed  Google Scholar 

Malone ER, Oliva M, Sabatini PJB et al (2020) Molecular profiling for precision cancer therapies. Genome Med 12:8. https://doi.org/10.1186/s13073-019-0703-1

Article  PubMed  PubMed Central  Google Scholar 

Pankiw M, Brezden-Masley C, Charames GS (2023) Comprehensive genomic profiling for oncological advancements by precision medicine. Med Oncol 41:1. https://doi.org/10.1007/s12032-023-02228-x

Article  CAS  PubMed  Google Scholar 

Swain MG, Lai MY, Shiffman ML et al (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593–1601. https://doi.org/10.1053/j.gastro.2010.07.009

Article  CAS  PubMed  Google Scholar 

Manns MP, Pockros PJ, Norkrans G et al (2013) Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 20:524–529. https://doi.org/10.1111/jvh.12074

Article  CAS  PubMed  Google Scholar 

Qian C, Dai N, Xu M et al (2020) ctDNA facilitated the diagnosis of a patient with synchronous urothelial carcinoma and non-small cell lung cancer: case report. Ann Transl Med 8:1323. https://doi.org/10.21037/atm-20-6552

Article  PubMed  PubMed Central  Google Scholar 

Kasi PM (2022) Tumor-informed versus plasma-only liquid biopsy assay in a patient with multiple primary malignancies. JCO Precis Oncol 6:e2100298. https://doi.org/10.1200/PO.21.00298

Article  PubMed  PubMed Central  Google Scholar 

Hemenway G, Tierno MB, Nejati R et al (2022) Clinical utility of liquid biopsy to identify genomic heterogeneity and secondary cancer diagnoses: a case report. Case Rep Oncol 15:78–85. https://doi.org/10.1159/000521841

Article  Google Scholar 

Huang Q, Mitsiades I, Dowst H et al (2023) Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. npj Precis Oncol 7:123. https://doi.org/10.1038/s41698-023-00467-9

Article  CAS  PubMed Central  Google Scholar 

Vogt A, Schmid S, Heinimann K et al (2017) Multiple primary tumours: challenges and approaches, a review. ESMO Open 2:e000172. https://doi.org/10.1136/esmoopen-2017-000172

Article  Google Scholar 

Bell RJ, Rube HT, Kreig A et al (2015) The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348:1036–1039. https://doi.org/10.1126/science.aab0015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Totoki Y, Tatsuno K, Covington KR et al (2014) Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46:1267–1273. https://doi.org/10.1038/ng.3126

Article  CAS  Google Scholar 

Nault JC, Mallet M, Pilati C et al (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. https://doi.org/10.1038/ncomms3218

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nault JC, Zucman-Rossi J (2016) TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol 40:9–14. https://doi.org/10.1016/j.clinre.2015.07.006

Article  CAS  PubMed  Google Scholar 

Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961. https://doi.org/10.1126/science.1230062

Article  CAS  PubMed  Google Scholar 

Huang FW, Hodis E, Xu MJ et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959. https://doi.org/10.1126/science.1229259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026. https://doi.org/10.1073/pnas.1303607110

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinde I, Munari E, Faraj SF et al (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73:7162–7167. https://doi.org/10.1158/0008-5472.CAN-13-2498

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell RJA, Rube HT, Xavier-Magalhães A et al (2016) Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res 14:315–323. https://doi.org/10.1158/1541-7786.MCR-16-0003

Article  CAS  PubMed  PubMed Central  Google Scholar